Abstract
Quinoline-3-carboxamides (Q substances) are small molecule compounds with anti-inflammatory properties. In this study, we used one of these substances, Paquinimod, to treat a novel model for chronic liver inflammation and liver fibrosis, the NOD-Inflammation Fibrosis (N-IF) mouse. We show that treatment of N-IF mice significantly reduced inflammation and resulted in the regression of fibrosis, even when the treatment was initiated after onset of disease. The reduced disease phenotype was associated with a systemic decrease in the number and reduced activation of disease-promoting transgenic natural killer T (NKT)-II cells and their type 2-cytokine expression profile. Paquinimod treatment also led to a reduction of CD115+ Ly6Chi monocytes and CD11b+ F4/80+ CD206+ macrophages.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Cytokines / metabolism
-
Disease Models, Animal
-
Immunologic Factors / pharmacology*
-
Liver Cirrhosis / drug therapy*
-
Liver Cirrhosis / metabolism
-
Liver Cirrhosis / pathology
-
Macrophages / drug effects
-
Macrophages / metabolism
-
Macrophages / pathology
-
Mice, Inbred NOD
-
Mice, Transgenic
-
Monocytes / drug effects
-
Monocytes / metabolism
-
Monocytes / pathology
-
Natural Killer T-Cells / drug effects
-
Natural Killer T-Cells / metabolism
-
Natural Killer T-Cells / pathology
-
Quinolines / pharmacology*
Substances
-
Cytokines
-
Immunologic Factors
-
Quinolines
-
quinoline-3-carboxamide
Grants and funding
This work was supported by (DH) NovoNordisk Fonden, NNF15OC0016146, Diabetesfonden, DIA2017-221, Barndiabetesfonden, and the Lundberg Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.